z-logo
open-access-imgOpen Access
Study of extended-spectrum β-lactamase-producing bacteria from urinary tract infections in Bangladesh
Author(s) -
Shahidul Ahmed Khan,
Farahnaaz Feroz,
Rashed Noor
Publication year - 2013
Publication title -
tzu-chi medical journal/cí-jì yīxué
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.343
H-Index - 15
eISSN - 2223-8956
pISSN - 1016-3190
DOI - 10.1016/j.tcmj.2013.01.008
Subject(s) - enterobacter , acinetobacter , microbiology and biotechnology , antimicrobial , antibiotic resistance , medicine , klebsiella , enterococcus , pseudomonas aeruginosa , staphylococcus aureus , escherichia coli , bacteria , antibiotics , biology , biochemistry , genetics , gene
ObjectiveProduction of β-lactamase by pathogens causing urinary tract infection (UTI) has been demonstrated to increase resistance to antimicrobial agents. The current study showed the prevalence of uropathogens and their antimicrobial susceptibilities, based on extended-spectrum β-lactamase (ESBL) production, in Dhaka.Materials and MethodsThe prevalence of uropathogens and their antimicrobial resistance patterns were identified in 200 isolates from patients with UTI. Double-disc diffusion and E tests were performed to determine the presence of ESBL-producing strains.ResultsThe most common pathogen was Escherichia coli (57%), followed by Enterococcus spp. (10.5%), Klebsiella spp. (11%), Staphylococcus spp. (4%), Pseudomonas spp. (10%), Acinetobacter spp. (5%), and Enterobacter spp. (9%). ESBL production occurred more frequently in Klebsiella spp. (72.7%) than E. coli (53.5%), and Enterobacter spp. (66.7%).ConclusionThe current investigation found E. coli to be the most common uropathogen. Overall, the higher frequency of antimicrobial resistance as well ESBL production by the most common pathogens found in this study may demonstrate a public health threat and therefore, the community should be made aware of this problem

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here